Objectives of the present study were to identify predictors of the recurrence of intrahepatic cholangiocarcinoma (ICC), and to evaluate the survival benefit of adjuvant chemotherapy and surgical treatment for ICC recurrence. A multi-institutional retrospective study was carried out in 356 patients with ICC who underwent curative surgery at one of 14 institutions belonging to the Kyushu Study Group of Liver Surgery. A total of 214 patients (60%) had recurrence. Predictors of ICC recurrence were as follows: positive for pathological intrahepatic metastasis (im), positive for lymph node metastasis (n), positive for pathological lymphatic infiltration (ly), pathological bile duct invasion (b), and tumor size ≥4.4 cm. Adjuvant chemotherapy was given to 120 patients (34%) and, in the patients with im or tumor size ≥4.4 cm, adjuvant chemotherapy showed a survival benefit. Only 37 patients (17%) underwent surgical treatment for ICC recurrence. The surgical treatment resulted in a good 5-year survival rate (44%), which is similar to the rate obtained by the first operation for primary ICC. Prognosis of patients with primary im after the second operation was significantly worse (5-year survival 18%) compared to patients without primary im. Primary im+ should be considered a contraindication for surgical treatment for ICC recurrence.
| INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is a rare disease; however, it has a relatively highly prevalence in Asia and in the USA, at over 1/100 000 population ratio. 1 In the USA, the incidence of ICC has increased by 165% over the past 30 years, and surgical resection remains the only curative treatment option. 2 Surgical results for ICC remain unsatisfactory because of the high rate of recurrence, reported to be 53-71%. [3] [4] [5] Several studies showed that cure after resection of ICC is an elusive goal, and there is an increasing awareness of the need for predictors of recurrence such as tumor size ≥5.0 cm, 3, 6 lymph node metastasis, 3,7 macrovascular invasion, 3 satellite liver nodules, 7 and pathological perineural invasion (pn). 7 To improve patient survival after ICC resection, optimal treatment strategies must be identified for both ICC recurrence and prevention of recurrence such as adjuvant chemotherapy.
The major recurrent focus of ICC has been reported to be the liver, and the rate of ICC recurrence in the liver is approximately 60%. 3, 5 Considerable interest has been paid to various treatment options against ICC recurrence such as surgical treatment, [6] [7] [8] chemotherapy, 9 radiation therapy, 7 radiofrequency ablation (RFA), 10, 11 and transarterial chemotherapy 12, 13 with various degrees of success. In recent reports, aggressive surgical treatment for ICC recurrence led to good patient survival after recurrence, with a 3-year overall survival (OS) rate of 25%, 14 40%, 6 and 100%. 7 However, the efficacy of this strategy remains unclear because of the small numbers of patients who underwent surgical treatment for ICC recurrence in those studies (ie from four to 10 patients). 6, 7, 14 In the present study, we attempted to identify predictors of ICC recurrence after curative surgeries, and we evaluated the survival benefit of adjuvant chemotherapy and surgical treatment for ICC recurrence in a multi-institutional retrospective study conducted by Kyushu Study Group of Liver Surgery for an examination of a large patient sample size.
2 | ME TH ODS 
| Surgical techniques and follow-up methods
Details of our surgical techniques and patient follow-up methods have been reported previously. [15] [16] [17] Major hepatectomies with bile duct resection were carried out when bile duct invasion of ICC was suspected to affect the first branch of the hepatic duct. Partial hepatectomies were carried out in cases of peripheral ICC without bile duct invasion. When surgeons believed it would be better to confirm the surgical margins, the resected stump was used for frozen pathology. 15 The right and left lobes of the liver have different routes of lymphatic drainage, and thus the style of lymph node dissection was different according to tumor location on the right or left lobe. 16 We generally did not carry out regional lymph node dissection in patients with peripheral ICC without macroscopic swelling lymph nodes. Using all significant variables in the univariate analysis, we used multivariate logistic regression models to determine independent predictors of ICC recurrence ( Table 2 ). Receiver operating character- 
| Survival benefit of adjuvant chemotherapy
Adjuvant chemotherapy was given to 120 patients (34%), including gemcitabine-based (67 patients; 56%), S-1 (19 patients; 16%), and other chemotherapies (34 patients; 28%). Figure 1A demonstrates that adjuvant chemotherapy did not provide a survival benefit in the series of all patients (P=.5898). To analyze the survival benefit of adjuvant chemotherapy especially in patients with independent predictors of ICC recurrence, we carried out subgroup analyses concerning patient survival after surgery, and the results are summarized in Table 3 . In patients with im (P=.0110) and in patients with tumor size ≥4.4 cm (P=.0224), adjuvant chemotherapy had a significant survival benefit. Figure 2A demonstrates that the patients who underwent surgical treatment had significantly better survival compared to those with non-surgical treatment (n=123) and best supportive care (BSC) (n=54, P<.0001). The 2-year survival rate of the patients who underwent surgical treatment was 87% (31% in the non-surgical treatment group, and 6% in the BSC group), and the 5-year survival was 44%.
Results of our comparisons of short-term surgical outcomes between patients with a first operation against primary ICC and those with a second operation against ICC recurrence are summarized in Table 4 . The second operations were small-scale, and operation time was significantly shorter (462AE285 vs 304AE147 min, P=.0020) and blood loss was significantly less (1450AE1605 vs 582AE603 g, P=.0025). Therefore, the measures of short-term surgical outcome such as mortality (4% vs 0%, P<.0001), morbidity (36% vs 5%, P<.0001), and duration of hospital stay (31AE28 vs 17AE9 days, P=.0059) were better in the patients with the second operations.
As for patient survival, Figure 2B demonstrates that there was no significant difference between the patients with a first operation (5-year survival 48%) and those with a second operation (5-year survival 44%) (P=.9261).
Prognostic factors for overall survival in the second operations were analyzed, and the results are summarized in Table 5 . Only one patient with primary n (1.5%), and two patients with primary ly (4.2%) had a second operation. Factors associated with recurrent ICC such as multiple recurrences, extrahepatic metastasis, and disease-free interval<1 year cannot predict patient survival after the second operation; however, the factor "im (+)" associated with primary ICCs is the only poor prognostic factor in the second operation. The 3-year survival rate of patients without primary im (-) was 81%, whereas that of patients with primary im (+) was 18%.
The survival curves after the second operation related to solitary or multiple recurrence (P=.8256) and to the presence or absence of primary im are provided in Figure 3A and B, respectively.
| DISCUSSION
There have been several reports, including our own, concerning the poor prognostic factors or predictors of recurrence after curative operation for ICC. 3, 6, 7, 15 In this report, we identified five independent predictors of ICC recurrence such as im (+), n (+), ly (+), b (+), and tumor size ≥4.4 cm. The independent poor prognostic factors in DFS were the same as these five factors (data not shown 7 and CA19-9 ≥135 U/mL. 21 In the present series, median DFS was 6.0 months in the patients with n (n=80) and 8.5 months in the patients with tumor size ≥4.4 cm. Therefore, neoadjuvant chemotherapy would be a potent treatment option for these patients. The use of neoadjuvant chemotherapy can contribute to patient selection for surgery, based on whether or not distant metastasis appears within several months of the chemotherapy.
However, as we reported, the preoperative diagnosis for n is difficult even by positron emission tomography-computed tomography, the sensitivity of which is low at 31.2%. b, pathological bile duct invasion; DFI, disease-free interval; im, pathological intrahepatic metastasis.
survival benefit of adjuvant chemotherapy using propensity scorematched modeling. 9 In their series, the propensity score-matched In the present series, ICC recurrence occurred in 214 patients (60%), and the major recurrent focuses were the liver (37%), lymph nodes (29%), lung (14%), and peritoneum (12%). Recent reports also mentioned that the major ICC recurrent focus was the liver, and the rate of intrahepatic recurrence was relatively high (60%) compared to our results. 3, 5 In our 81 patients with lymph node recurrence, regional lymph node recurrence occurred in 13 patients only (16%). Therefore, we propose that aggressive and routine lymph node dissection in patients with ICC cannot always contribute to prevention of lymph node recurrence after operation. 15, 16 Although our series is the larger patient population compared to previous reports, 6, 7, 14 surgical treatments for ICC recurrence were carried out in 37 patients only (17%). This rate is extremely low compared to that of repeat resection for recurrent hepatocellular carcinoma at 53%. 24 In previous reports, surgical treatment for ICC recurrence was carried out only in cases of intrahepatic recurrence; however, our series included 18 patients (49%) who underwent surgical treatment for extrahepatic recurrence. Patient prognosis after surgical treatment for extrahepatic ICC recurrence was relatively good (3-year survival 77%)
compared to that for intrahepatic ICC recurrence (3-year survival 58%), and thus extrahepatic ICC recurrence should not be considered a contraindication for surgical treatment.
We observed that the prognoses of our patients who underwent surgical treatment for ICC recurrence were significantly better compared to patients with non-surgical treatment or BSC, and 5-year survival after the second operation reached 44%. This value was almost the same as that of the first operation for primary ICC (48%), and there was no significant difference between the survival curve of patients with first and second operations (Fig 2B) . Short-term surgical results such as mortality (4% vs 0%; P<.0001) and morbidity (36% vs 5%; P<.0001) in patients with a second operation were significantly better than those in patients with the first operation (Table 4) . One of the major reasons for these better short-term surgical outcomes in patients with a second operation was the early detection of tumor as a result of strict postoperative follow up, and this led to less-invasive surgeries. Mean tumor size in the second operation was significantly smaller than that in the first operation (2.7 vs 4.8 cm; P=.0005). Our results demonstrated that surgical treatment for ICC recurrence is feasible, and provides a survival benefit in patients with ICC recurrence.
The most important and difficult problem is to determine whether ICC recurrence requires surgical treatment. In our series, all patients with a single ICC recurrence (n=24) underwent surgical treatment irrespective of the recurrent focuses. The prognosis of patients with im at the first operation was significantly worse compared to those without im after the second operation (P=.0019), and the 3-year survival was low (18%). Because of those aggressive recurrence patterns, only one patient with primary n (1.5%), and two patients with primary ly (4.2%) had a second operation. However, all three of these patients had a single lymph node recurrence, and they had relatively good survival after the second operation; 6.4 years (alive), 4.5 years (died), and 1.8 years (died).
Limitations of the present study are the study's multi-institutional retrospective design and the long-term interval; in addition, our results might be biased as a result of the varying therapeutic policies of the many physicians. However, the number of patients with recurrent ICC who undergo a second operation is quite small and, in this multi-institutional study, we therefore made it a priority to collect as large a number of such patients as we could. As a result, 37
patients with a second operation were included. This number is by far largest reported of such patients. Of course, prospective studies with the same therapeutic policies for ICC recurrence are necessary to confirm our results.
In conclusion, the rate of ICC recurrence after curative operation in our series was high at 60%. 
